ViiV Healthcare

#ABPI #Bispecific Antibodies #Clinical trial #Follicular lymphoma #HIV #National Institute for Health and Care Excellence (NICE) #Novo Nordisk #Nuclear medicine #Prostate cancer #UK #ViiV Healthcare

DDW Highlights: 3 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, more effective treatments were found for both HIV and chronic wounds. Elsewhere, €40,000… Read More

#Podcasts

#ABPI #Bispecific Antibodies #Clinical trial #Follicular lymphoma #GLP-1 #HIV #National Institute for Health and Care Excellence (NICE) #Novo Nordisk #Nuclear medicine #Obesity #Prostate cancer #UK #ViiV Healthcare #Weight loss

This week in Drug Discovery (23 – 27 February) 

News round-up for 23 – 27 February by Bruno Quinney, Content Team at DDW.  This week in drug discovery, more effective treatments have been found for both HIV and chronic wounds. Elsewhere, €40,000 is up for grabs in prostate cancer research.  The top stories:   … Read More

#News

#HIV #The New England Journal of Medicine #ViiV Healthcare

Injectable HIV drug more effective than daily oral therapy 

An injectable treatment for HIV could be more effective than a daily oral therapy, data suggests.  Results from the LATITUDE study of Cabenuva (cabotegravir + rilpivirine), a long-acting injectable developed by HIV specialist ViiV Healthcare, show the switch to the injectable reduced risk of virological failure by nearly half compared to… Read More

#News

Chinese flag
#China #HIV #Regulatory #ViiV Healthcare

Chinese regulator approves complete HIV-1 injectable

The National Medical Products Administration (NMPA) of China has approved ViiV Healthcare’s Vocabria (cabotegravir injection) in combination with Janssen's Rekambys (rilpivirine long-acting injection) for the treatment of HIV-1 infection. Cabotegravir injection and tablets were approved in China in July 2023. Cabotegravir injection is indicated in adults who are virologically suppressed,… Read More

#News #Regulatory